Establishment and characterization of NCC-GCTB1-C1 : a novel patient-derived cancer cell line of giant cell tumor of bon
- PDF / 1,095,953 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 41 Downloads / 199 Views
CELL LINE
Establishment and characterization of NCC‑GCTB1‑C1: a novel patient‑derived cancer cell line of giant cell tumor of bone Rei Noguchi1 · Yuki Yoshimatsu1 · Takuya Ono1 · Akane Sei1 · Kaoru Hirabayashi2 · Iwao Ozawa3 · Kazutaka Kikuta4 · Tadashi Kondo1 Received: 20 July 2020 / Accepted: 10 August 2020 © Japan Human Cell Society 2020
Abstract Giant cell tumor of bone (GCTB) is a rare osteolytic bone tumor, accounting for approximately 5% of all primary bone tumors. GCTB is characterized by unique giant cells. It is also characterized by recurrent mutations in the histone tail of the histone variant H3.3, H3F3A, on chromosome 1, therapeutic implications of which have not been established yet. There are few effective standardized treatments for GCTB, and a novel therapy has long been required. Patient-derived cancer cells have facilitated the understanding of mechanisms underlying the etiology and progression of multiple cancers. Thus far, only 10 GCTB cell lines have been reported, and none of them are publicly available. The aim of this study was to develop an accessible patient-derived cell line of GCTB, which could be used as a screening tool for drug development. Here, we describe the establishment of a cell line, designated NCC-GCTB1-C1, from the primary tumor tissue of a male patient with GCTB on the right distal radius. NCC-GCTB1-C1 cells were maintained as a monolayer culture for over 23 passages for 7 months. These cells exhibited continuous growth, as well as spheroid formation and invasive ability. Using an oncology agent screen, we tested the effect of anticancer drugs on the proliferation of NCC-GCTB1-C1 cells. The cells displayed a remarkable response to romidepsin and vincristine. Thus, we established a novel GCTB cell line, NCC-GCTB1-C1, which could be a useful tool for studying GCTB tumorigenesis and the efficacy of anticancer drugs. Keywords Giant cell tumor of bone · Cell line · Anticancer drug screen · NCC-GCTB1-C1 · GCTB in vitro model
Introduction
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13577-020-00415-w) contains supplementary material, which is available to authorized users. * Tadashi Kondo [email protected] 1
Division of Rare Cancer Research, National Cancer Center Research Institute, 5‑1‑1 Tsukiji, Chuo‑ku, Tokyo 104‑0045, Japan
2
Division of Diagnostic Pathology, Tochigi Cancer Center, 4‑9‑13 Yohnan, Utsunomiya, Tochigi 320‑0834, Japan
3
Division of Hepato‑Biliary‑Pancreatic Surgery, Tochigi Cancer Center, 4‑9‑13 Yohnan, Utsunomiya, Tochigi 320‑0834, Japan
4
Division of Musculoskeletal Oncology and Orthopaedics Surgery, Tochigi Cancer Center, 4‑9‑13 Yohnan, Utsunomiya, Tochigi 320‑0834, Japan
Giant cell tumor of bone (GCTB) is a rare osteolytic bone tumor, accounting for approximately 5% of all primary bone tumors [1, 2]. It is characterized by the presence of unique giant cells, which are formed by the fusion of multiple individual cells into a single, large cell. GCTB typically occurs, in decreasi
Data Loading...
